Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. - Wikidata - wikimedia - TriplyDB

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

http://www.wikidata.org/entity/Q39981784

about

Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms Malignant peripheral nerve sheath tumor in neurobifromatosis type-1: two case reports.Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies.Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis The NF1 gene revisited - from bench to bedside.Impaired Pten expression in human malignant peripheral nerve sheath tumours.Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden.Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.Wilms' tumor gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor sNF96.2 cell line.Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.Deconvoluting mTOR biology Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol.Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine.Secretome survey of human plexiform neurofibroma derived Schwann Cells reveals a secreted form of the RARRES1 protein.Fatty acid synthase is a metabolic oncogene targetable in malignant peripheral nerve sheath tumors.MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors.Triterpenoid saponin flaccidoside II from Anemone flaccida triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors via the MAPK-HO-1 pathway Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance Development and clinical application of an integrative genomic approach to personalized cancer therapy How does the Schwann cell lineage form tumors in NF1?Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways.Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.The ecology of brain tumors: lessons learned from neurofibromatosis-1.High grade malignant peripheral nerve sheath tumors: outcome of 62 patients with localized disease and review of the literature.The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis.Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.

P2860

Q28305337-853DD2E0-D760-4EC4-8A0B-F89ABE172A2B Q30457681-E4E09033-1DB2-4ECD-AA0C-1DEB3FF97F42 Q30485989-58F8F0D6-D565-43D5-9FC9-72545F4BB4E6 Q30524134-08CE4862-7BD3-433E-B6B0-ACFC416CC881 Q33688908-9DDE69C5-3803-443B-A344-E814E41BC6E6 Q33737662-E75CC4C9-D2AA-4A0B-A1E5-0DFBEE02F68F Q33763742-6643C1F7-DE6E-4DE8-8ABA-C9FB17C7A154 Q33940402-8754B456-94B9-4D76-86BA-30AC35B77A1D Q34022861-031F83FD-DA1F-40EF-87DC-FA819B7DFB05 Q34199631-A2DEAFEA-5903-41BD-85E5-8C00AD5B2EBB Q34227509-DAEFC89C-5109-471A-BBB0-C80359C0A8FA Q34471826-E2428895-FC8B-4182-963C-D2064E9F2E0E Q34797452-5D8D4A5D-BA71-45A4-84B7-CC116A2585B2 Q35021348-165644C3-E381-4FFF-86B6-5F4F43C91A03 Q35489149-5D9298CF-6DC6-4695-83DE-E8677E3552FA Q35613659-B9B05009-2C59-4A15-A672-8DD2805AC0E6 Q35788825-3DEE20C2-5EC7-4DDE-961B-814D20F69DB2 Q35788976-856111FD-F3A6-4043-B992-B33540884BFA Q35801388-B2EC5AC5-079B-4ADF-8F50-4066D17741CD Q35804635-E8833B7A-F6E9-48B0-A436-56078AF74474 Q35822579-167F4D81-AB8C-47CB-9A27-B54C01711AE3 Q36197438-2B93E65E-E197-4E3B-85CD-F4A873D9EE81 Q36250734-C3BF9528-DA93-42B2-B8F3-D7AA5383241E Q36497139-1E0CE1BB-1E2A-4E31-BB2C-4EE351C49CCB Q36675171-0F55B44E-D89F-4FA0-B36E-5CB3D526776E Q36787769-4630A267-A070-4D45-83AB-90F42F831A3D Q36920489-37CC8B8F-6D7B-4B76-B05A-7A551C2FC2C0 Q36954557-F1702B08-DB9C-48BA-88A2-6F56A3176B29 Q37120518-6903C1E0-CB56-484E-97B4-23C7212B5645 Q37517660-F95B0CF0-1BED-48D6-9CA1-EA629B06BD0F Q37582080-489974BC-599B-4D40-BF39-F05EBEA08C76 Q37616238-BE646E21-36A8-450E-A763-0113FB16257E Q37625501-D533364B-A96C-40D6-A2F3-1062EBB4E12B Q37795414-422A3205-F0E9-4535-AFF9-85F3C692268B Q37809458-CDA352D0-1DDF-4D98-8FBD-792053CC1F49 Q37838069-5147BCA8-EEF8-4B41-A5CE-783B0B859A0E Q38666243-14E1A922-6A76-4E2A-931C-BB3A336B2204 Q38769437-6302A0E3-0B13-42EC-9B14-08B84DD369F6 Q38792018-114850D1-A864-402A-9762-FC3AFE26AF5C Q38797046-54BBB074-665F-4809-B252-91D892CBB45E

P2860

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

http://www.wikidata.org/entity/Q39981784

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Effective in vivo targeting of ...... eripheral nerve sheath tumors.

@en

Effective in vivo targeting of ...... eripheral nerve sheath tumors.

@nl

type

label

Effective in vivo targeting of ...... eripheral nerve sheath tumors.

@en

Effective in vivo targeting of ...... eripheral nerve sheath tumors.

@nl

prefLabel

Effective in vivo targeting of ...... eripheral nerve sheath tumors.

@en

Effective in vivo targeting of ...... eripheral nerve sheath tumors.

@nl

P1433

Q39981784-E6074B8C-B646-4677-8278-53818B20BFB0

P1476

Q39981784-EF68A10F-C27C-41FB-84AA-608B72C1D456

P2093

Q39981784-134AB4A1-86D5-4A8D-97B3-9D78975995D0

Q39981784-20F49D5F-0F49-4B2B-AF51-C86E3E81C0B4

Q39981784-248EFED4-AA63-4EA0-B2EF-216070250496

Q39981784-268BF7DB-89EB-4666-82E2-DCC9E437ED57

Q39981784-75E856D5-E38D-437D-A297-28854B2EBB15

Q39981784-92E821FD-74FC-47B9-87CE-A541CE787861

Q39981784-ACCDB87C-7DD5-41E2-B844-419844EC36DD

Q39981784-B3996547-AF18-485F-B65F-68183203741D

Q39981784-B4A2F958-62F5-4824-BE93-E2F4D2B737DD

Q39981784-E8A754FD-D0AF-4807-A2F9-E7A468FA488F

P2860

Q39981784-03A77AAC-44ED-415F-9D45-C4DA8E511B88

Q39981784-0909BC36-9638-441D-8EB5-53021368C889

Q39981784-254FF90F-6024-487D-B6B9-5B79927E78E2

Q39981784-2A3C9C72-9321-4368-A949-35BB5C390237

Q39981784-3147CDF2-1FCC-4264-ABBF-F553968D5371

Q39981784-37AB96BB-75B9-4E80-8780-8EF5F21DCB9A

Q39981784-382040AD-CE34-4A9A-8DF8-477B0CF7B47E

Q39981784-4A224AF8-5E9C-4324-B8E6-AE47CBB02C82

Q39981784-4A8E750D-A79C-4D05-A0A9-8896B42F4C9C

Q39981784-50FD1028-2E17-4954-91F4-5FBD395F4E7A

P304

Q39981784-2D6660B7-1621-48D7-916C-596E3A385FE6

P31

Q39981784-F04C8533-601D-439D-B08A-1C62EB6CB912

P356

Q39981784-F6F08BAF-7A20-47C3-8909-EB23963431E3

P433

Q39981784-EC0FD74F-49AD-4BA1-8072-4B179B3C61B3

P478

Q39981784-07A35437-7DD0-462C-9260-DA58C305DBFF

P577

Q39981784-26844325-B0D4-4F97-9B2B-B062D012263A

P698

Q39981784-42BC8D40-A3AA-4F46-9A01-60C452E591D3

P932

Q39981784-F2D96E1D-3813-4141-A2BC-DF1474B6DB90

P356

1535-7163.MCT-07-2335

P1433

Molecular Cancer Therapeutics

P1476

Effective in vivo targeting of ...... eripheral nerve sheath tumors.

@en

P2093

George Thomas

http://www.w3.org/2001/XMLSchema#string

Gunnar Johansson

http://www.w3.org/2001/XMLSchema#string

Heidi A Lane

http://www.w3.org/2001/XMLSchema#string

John Perentesis

http://www.w3.org/2001/XMLSchema#string

Margaret H Collins

http://www.w3.org/2001/XMLSchema#string

Mi-Ok Kim

http://www.w3.org/2001/XMLSchema#string

Nancy Ratner

http://www.w3.org/2001/XMLSchema#string

Sara C Kozma

http://www.w3.org/2001/XMLSchema#string

Takahiro Nobukuni

http://www.w3.org/2001/XMLSchema#string

Timothy P Cripe

http://www.w3.org/2001/XMLSchema#string

P2860

Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Malignant peripheral nerve sheath tumours in neurofibromatosis 1

Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity

Localization of Rheb to the endomembrane is critical for its signaling function

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

Rheb binds and regulates the mTOR kinase

Upstream and downstream of mTOR

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

P304

1237-1245

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-07-2335

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18483311

http://www.w3.org/2001/XMLSchema#string

P932

2855168

http://www.w3.org/2001/XMLSchema#string